Control of human mesothelin-expressing tumors by DNA vaccines

Cl, Chang; Wu, Tong; Cc, Hung

doi:10.1038/sj.gt.3302974

Cited by 44 publications

(40 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although the biological functions of mesothelin remain largely unknown, restricted distributions of mesothelin in normal tissues and its overexpression in many tumors render it an interesting therapeutic target [12,[25][26][27][28]. In recent years, expression of mesothelin and its relationship between survival outcomes has been investigated in various tumor types [27][28][29][30][31][32][33].…”

Section: Discussionmentioning

confidence: 99%

Prognostic value of mesothelin expression in patients with triple negative and HER2-positive breast cancers

Bayoğlu

Kucukzeybek

Küçükzeybek

et al. 2015

Biomedicine & Pharmacotherapy

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Prognostic value of mesothelin expression in patients with triple negative and HER2-positive breast cancers

Bayoğlu

Kucukzeybek

Küçükzeybek

et al. 2015

Biomedicine & Pharmacotherapy

View full text Add to dashboard Cite

“…24,25 Although the biological functions of mesothelin including enhancing chemotherapy resistance and inducing tumor invasion have been established, 24,26 studies targeting mesothelin as an ovarian cancer antigen are lacking. Several clinical trials on mesothelin target therapies are ongoing, most of which are focused on antibody or adaptive T-cell transfer.…”

Section: Discussionmentioning

confidence: 99%

Mesothelin-specific cell-based vaccine generates antigen-specific immunity and potent antitumor effects by combining with IL-12 immunomodulator

Chiang

et al. 2015

Gene Ther

View full text Add to dashboard Cite

Ovarian cancer is a gynecologic malignancy with a high mortality rate. In the present study, we developed a novel cell-based vaccine, Meso-VAX, to generate mesothelin antigen-specific immune responses and immunotherapy against ovarian cancer. Mesothelin, a secreted protein anchored at the cell membrane, has recently been identified as a potential new tumor antigen for ovarian cancer. In this study, mice vaccinated with Meso-VAX and adeno-associated virus (AAV)-IL-12 exhibited dramatic increases in the number of mesothelin-specific CD4(+) helper and CD8(+) cytotoxic T-cell precursors, higher titers of anti-mesothelin Abs and in vitro tumor killing activity, and all of these mice were tumor-free after 60 days of tumor challenge. In addition, a significant reduction in peritoneal tumors and longer survival were noted in the mice vaccinated with Meso-VAX combined with AAV-IL-12. CD4(+) helper and CD8(+) cytotoxic T lymphocytes were essential for the antitumor effect generated by Meso-VAX combined with AAV-IL-12. The post-vaccination sera of the mice vaccinated with Meso-VAX and AAV-IL-12 also showed mesothelin-specific complement-dependent cell-mediated cytotoxicity. Our results suggest that a Meso-VAX cell-based vaccine combined with AAV-IL-12 can generate antigen-specific immunological responses and antitumor effects on ovarian cancer.

show abstract

“…Therefore, early evidence suggests that FDG-PET may have a useful role in evaluating MPM response to therapy. In one study [35,36], evidence of response was reported as early as after one cycle of chemotherapy by quantitative semi-automated volumebased FDG-PET analysis performed to obtain the TGV of tumor (Table 1).…”

Section: Response To Chemotherapy/radiationmentioning

confidence: 99%

Current Evidence Base of FDG-PET/CT Imaging in the Clinical Management of Malignant Pleural Mesothelioma: Emerging Significance of Image Segmentation and Global Disease Assessment

et al. 2010

View full text Add to dashboard Cite

Increasingly, integrated positron emission tomography-computed tomography (PET/CT) imaging is playing a crucial role in the assessment of patients with known or suspected malignant pleural mesothelioma (MPM). Based on the data reported in the literature, this combined modality is likely to become the instrument of choice for examining patients of MPM. The research on this subject has focused on the following five domains: (1) differentiation of MPM from other benign pleural diseases, (2) preoperative staging for the selection of appropriate candidates for surgery, (3) evaluation for therapy response and post-treatment surveillance for recurrence, (4) prognostication based upon the intensity of 2-deoxy-2-[(18)F]fluoro-D-glucose (FDG) uptake, and (5) planning of radiotherapy. These represent the bases for critical decision making in the management of mesothelioma, and FDG-PET/CT offers potential advantages over conventional CT imaging and thus can play a pivotal role in this regard. Optimal characterization of this potentially fatal disease with a high negative predictive value for MPM, superior capability for cancer staging initially and at the later course of disease, and ability for measuring therapeutic response and the precise determination of the target volume for radiotherapy planning represent distinct advantages of this promising molecular imaging tool. In this communication, we have explored the promising role of integrated FDG-PET/CT in the overall management of this serious malignancy. From the available data, the major role of PET-CT at present appears to be in the preoperative disease staging, response to treatment assessment, and post-treatment disease surveillance of MPM. In all these three areas, PET-CT convincingly shows better results than conventional anatomical imaging alone and thereby can aid in exploring novel therapeutic approaches. Disease prognosis and radiotherapy planning are evolving areas where this modality has demonstrated significant promise, but this has to be investigated further. The differentiating of MPM from benign pleural disease is a challenging issue; though in limited studies, it has shown promising results, single standardized uptake value (SUV) cutoff technique cannot be the optimal way for this purpose. Dual time point and delayed imaging helps further in this setting; however, more data require to be accrued in this area. We, in this review, have also discussed the feasibility of a new method of image segmentation based on an iterative thresholding algorithm, which permits definition of the boundaries of lesions based on PET images alone to provide lesional metabolically active tumor volumes, lesional partial volume corrected SUV (PVC-SUV) measurements, lesional PVC metabolic burden (PVC-MB) (calculated as the product of lesional MVP and lesional PVC-SUV), and whole body metabolic burden (WBMB) (calculated as the sum of lesional PVC-MB of all lesions). This global disease assessment, we believe, will be the way forward for assessing this malignancy with a non-invasive...

show abstract

Control of human mesothelin-expressing tumors by DNA vaccines

Cited by 44 publications

References 31 publications

Prognostic value of mesothelin expression in patients with triple negative and HER2-positive breast cancers

Prognostic value of mesothelin expression in patients with triple negative and HER2-positive breast cancers

Mesothelin-specific cell-based vaccine generates antigen-specific immunity and potent antitumor effects by combining with IL-12 immunomodulator

Current Evidence Base of FDG-PET/CT Imaging in the Clinical Management of Malignant Pleural Mesothelioma: Emerging Significance of Image Segmentation and Global Disease Assessment

Contact Info

Product

Resources

About